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Rosiglitazone,anagonistofperoxisomeproliferatoractivated receptor (PPARγ),improvesinsulinsensitivityby increasinginsulin-
stimulated glucose uptake into muscle tissue. This study was undertaken to assess changes in expression of PPAR-regulated genes
in muscle tissue following treatment of HIV-associated insulin resistance with rosiglitazone. Muscle gene expression was assessed
in twenty-two seronegative HIV subjects (control), 21 HIV-infected individuals with normal insulin sensitivity (HIV-IS) and 19
HIV-infected individuals with insulin resistance (HIV-IR). A subset of the HIV-IR group (N = 10) were re-evaluated 12 weeks
after treatment with 8mg/d of rosiglitazone. The HIV-IR group’s rosiglitazone-mediated improvement in insulin sensitivity was
highly correlated with increased expression of PPARγ and carnitine palmitoyl transferase-1 (CPT-1), (r = 0.87, P<. 001) and
(r = 0.95, P<. 001), respectively. The changes in PPARγ expression were also correlated with the changes in CPT1 expression
(r = 0.75, P = .009).The results suggest that rosiglitazone;may have a direct eﬀect on muscle tissue to improve insulin sensitivity.
1.Introduction
With the increased use of multiple antiretroviral regi-
mens including protease inhibitors, perturbations in glucose
metabolism including insulin resistance and diabetes melli-
tus have been reported in patients infected with HIV (e.g.,
[1–5]).Insulin resistance predisposes individuals to diabetes,
and insulin resistance and diabetes are also independent risk
factors for cardiovascular disease [6–8]. Since HIV-infected
individuals have additional risk factors for cardiovascular
disease including hyperlipidemia (e.g., [9]) and increased
visceral adiposity (e.g., [10]) with a demonstrably higher
risk of myocardial infarction [11], several studies have
investigated treatment of HIV-associated insulin resistance
with antidiabetic drugs [12–17].
In treating HIV-associated insulin resistance, the thiazo-
lidinedione, rosiglitazone has been used in several studies
[12–16]. Rosiglitazone was selected not only because of its
ability to improve insulin sensitivity, but also because of its
p o t e n t i a lt os t i m u l a t ea d i p o c yt ed i ﬀerentiation[18]s i n c et h e
insulin resistance in HIV disease is associated with changes
in body fat distribution including loss of adipose tissue from
the peripheral subcutaneous regions [1, 19, 20]. In our small
study [12] and those of others [13, 15, 16], improved insulin
sensitivity with rosiglitazone treatment was associated with
an improvement in body fat distribution, although altered
body fat has not been reported in all studies (e.g., [21, 22]).
Rosiglitazone is a highly selective agonist for the gamma
isoform of the peroxisome proliferator-activated receptor
(PPAR) family of ligand-activated transcription factors [23,
24]. The expression of PPAR-γ is high in adipocytes and low
in skeletal muscle. Because of the potential importance of
PPARγ in regulating adipogenesis and the higher expression
of PPARγ in adipocytes, Sutinen et al. examined adipose2 Pathology Research International
tissuegeneexpressioninindividualswithHIV-lipodystrophy
treated for six months with PPARγ agonist rosiglitazone.
Onlysmall changesin theexpression ofthe PPARγ andgenes
regulated by PPAR-γ such as PPAR-γ coactivator-1 (PGC-1),
adiponectin, and IL-6 were observed, with no changes in
other genes regulated by PPAR-γ including the genes for
lipoprotein lipase, fatty acid binding protein or fatty acid
translocases [25].
AlthoughPPAR-γ isonly marginally expressed in skeletal
musclecomparedtoadiposetissue,muscleistheprimary tis-
sue aﬀecting peripheral glucose disposal [26]. Since rosigli-
tazone improved peripheral glucose disposal, as assessed
by the hyperinsulinemic euglycemic clamp [12, 16], this
study was undertaken to assess changes in gene expression
in muscle tissue in individuals with HIV-associated insulin
resistance treated with rosiglitazone. The expression of
PPAR-responsive skeletal muscle genes was assessed from
skeletalmusclebiopsyspecimensbeforeandafter12weeksof
rosiglitazoneadministration. Forcomparison,theexpression
ofPPAR-responsive skeletalmusclegeneswasalso assessed in
uninfected control subjects as well as HIV-infected subjects
with and without impaired peripheral glucose uptake.
2.Materialsand Methods
2.1. Study Subjects. Gene expression was assessed using real-
time PCR with an MJ research opticon instrument (Bio-
Rad,Hercules,CA).RNAwasextractedfrommusclebiopsies
taken from 22 seronegative for HIV subjects (control), 21
HIV-infected individuals with normal insulin sensitivity
(HIV-IS) and 19 HIV-infected individuals with insulin resis-
tance (HIV-IR). Subjects were classiﬁed as insulin sensitive
if peripheral glucose disposal from a hyperinsulinemic-
euglycemicclamp[27]was greaterthan 1SD belowthemean
for control subjects, that is, glucose disposal was less than
6mg glucose per kg lean body mass per minute during an
infusion of 1.2mU insulin per kg body weight per minute.
Muscle samples for gene expression analysis were available
from only a subset of the HIV-IR group (N = 10) who took
8mg/d rosiglitazone (4mg of Avandia, Glaxo-SmithKline,
Research Triangle Park, NC, USA. twice daily) for 12 weeks
and studied again in the post-drug state. The exclusion
criteria included an acute illness within 3 months preceding
the study, a fasting glucose >126mg/dl, a criteria eliminate
individuals with hepatic insulin resistance or a random
(nonfasting) blood glucose of >200mg/dl, treatment for
diabetes mellitus, or liver function tests in excess of three
times normal values.
Subjects were monitored every 2 weeks for liver function
tests, complete blood counts, CD4 counts, and viral load.
In addition, blood pressure, weight, and physical appearance
were also assessed at each visit. The study was approved by
the Committee on Research involving Human Subjects at
Stony Brook University and all subjects signed an informed
consent form.
2.2. Insulin Sensitivity. Insulin sensitivity was determined as
the rate of infused glucose necessary to maintain euglycemia
during an infusion of insulin (hyperinsulinemic- euglycemic
clamp) [27]. Subjects were admitted to the General Clinical
Research Center the night before the study. The subjects
were administered a deﬁned snack (half a turkey sandwich)
at 10 PM and were then fasted until completion of the
procedure. At 7:00 a.m. the subjects were infused with
1.2mU insulin (Humulin, Eli Lilly)/kg body weight per
minute, suﬃcient to suppress hepatic glucose production in
otherinsulin-resistant states[28].Dextrosewasadministered
intravenously at variable rates to maintain plasma glucose
at 90mg/dl. Plasma glucose was assessed from arterialized
blood, obtained by the heated hand technique [29]. Insulin
sensitivity was determined between the second and third
hour of insulin infusion. To normalize for diﬀerences in
body composition, insulin sensitivity is expressed as mg
glucose/kg lean body mass (LBM) per minute. LBM was
determined by dual energy X-ray absorptiometry (DEXA,
model DPS, Lunar Radiation Co., Madison, WI) as previ-
ously described [1]. Insulin sensitivity data before and after
rosiglitazone treatment was available for only 9 subjects and
the improvement in insulin sensitivity with rosiglitazone has
been reported previously [12].
2.3. Skeletal Muscle Biopsies. Skeletal muscle biopsies were
obtained from the vastus lateralis, under sterile conditions
using a 6mm Bergstrom needle with vacuum assist. The
vastus lateralis is a mixed ﬁber-type muscle composed both
fast and slow twitch ﬁbers, in relatively equal proportion,
but the proportion is subject to perturbation as a function
o ft h en a t u r eo fe x e r c i s e[ 30, 31]. The outer aspect of the
thigh was shaved and cleansed using antiseptic soap. A small
incision was used to expose the muscle surface and to allow
the introduction of the needle. The vacuum was applied and
the biopsy obtained. The biopsy specimen was quickly freed
ofexcess blood, connectivetissue and fat and frozen in liquid
nitrogen. Pressure was applied until bleeding was stopped
and the incision closed using sutures and steri strips. The
frozen muscle tissue was subsequently ground to a powder
under liquid nitrogen and stored in liquid nitrogen until
processed for RNA extraction.
2.4. Gene Expression Analysis. Total RNA was extracted
from frozen muscle powder using RNeasy lipid tissue
minikit (Qiagen, Inc., Valencia, CA), according to the
manufacturer’s instructions. cDNA was prepared using Su-
perScript ﬁrst-strand synthesis system with random hex-
amer priming (Invitrogen Corp., Carlsbad, CA). Gene
expression was assessed using inventoried TaqMan gene
expression assays, run with standard curves generated
from plasmid DNA containing, either the I.M.A.G.E.
clones, clones obtained through collaboration or a cloned
PCR fragment spanning the amplicon used in Taq-
Man ampliﬁcation. Inventoried kits for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) Hs99999905 m1; li-
poprotein lipase (LPL) Hs00173425 m1; muscle-type car-
nitinepalmitoyl transferase 1 (CPT-1) Hs00992651 g1; ste-
royl CoA-desaturase (SCD) Hs00748952 s1; adiponectinPathology Research International 3
Table 1: Subject characteristics.
Control HIV-IS HIV-IR HIV-IR (treated)
(N = 22) (N = 21) (N = 19) (N = 10)
Gender (M/F) 10/12 13/8 8/11 4/6
Race/ethnicity (AA/H/C) 2/2/18 15/2/4 10/3/6 7/0/3
Age (y) 38 ±1.54 1 ±1.44 1 ±1.54 1 ± 2.3
BMI (kg/m2)2 5 .5 ± .92 8 ±1.42 7 ±.82 6 ± 1.0
Viral load (copies/mL) N/A 400 (40;34,320) 50 (40;16,291) 900 (40;16,291)
CD4+ cells (cells/mm3) 500 ±65.3 530 ±58.8 668 ± 73.8
PI, NRTI, NNRTI 2 2 1
PI, NRTI 12 7 4
NRTI, NNRTI 4 5 2
NRTI 0 1 0
No HIV meds 3 3 2
Triglycerides (mg/dL) 104 ±10.5 132 ± 14 324 ±79 259 ±57
Insulin sensitivity (mg glucose/kg LBM/min) 10.6 ±0.74 9.7 ± 0.43 4.4 ±0.90
∗ 4.3 ± 0.3
Values are means ± SEM except viral load which is expressed as median and range. AA: African American; C: Caucasian; H: Hispanic; PI: protease inhibitor;
NRTI: nucleosidereverse transcriptaseinhibitor; and NNRTI: nonnucleosidereverse transcriptaseinhibitor. HIV-IS: insulinsensitivityHIV subjects.HIV-IR:
insulin-resistant HIV subjects. HIV- IR (treated) denotes subjects with insulin resistance who were treated with rosiglitazone (8mg/d for 12 weeks). Insulin
sensitivity was determined with the hyperinuslinemic euglycemic clamp and is expressed as mg glucose per kg per lean body mass per minute. ∗Insulin
sensitivity in the HIV-IR group was lower than either the control or the HIV-IS group (P<. 001). The data on improvement in HIV-associated insulin
resistance with rosiglitazone treatment has been previously reported [12].
Hs00605917 m1 peroxisome proliferator-activated receptor-
alpha (PPAR-α) Hs00231882 m1; PPAR-γ Hs00234592 m1;
PPAR-δ Hs00602622 m1 and Δ9-cis retinoic acid receptor-
alpha (RXR-α) Hs00172565 m1 and TaqMan master mix
were obtained from Applied Biosystems (Foster City, CA).
ThesequencesfortheTaqManassaysareproprietary,andnot
available. I.M.A.G.E. clones for GAPDH (ID no. 3869809),
LPL (ID no. 5768614), CPT-1 (ID no. 5245486), SCD (ID
no. 3844850), PPAR-α (ID no. 6204635), PPAR-γ (ID no.
5198366), RXR-α (ID no. 3294824) were on obtained from
OpenBiosystems (Huntsville, AL). The clone for human
adiponectin was obtained from P. Scherer, Albert Einstein
Medical College (Bronx, NY). The sequence for PPAR-δ
was ampliﬁed from human adipose RNA using primers
CCCCAAGCTTAGTACATGTCCTTGTAGATC and CCC-
GGAATCCATGGAGCAGCCACAGGAGG, digested with
Bam H1 and Hind III and ligated into prepared pBluescript.
All reactions were run in triplicate in 20μl volumes and
the same samples were analyzed for the normalizing gene
(GAPDH) on the same plate.
2.5. Statistical Analysis. The data are expressed as means ±
SEM. Assessment of diﬀerences among groups was deter-
mined by ANOVA with Tukey adjustment for multiple test-
ing.Assessment beforeandafter treatment with rosiglitazone
was made with paired t-test. Correlations were assessed by
linear regression. Diﬀerences were considered signiﬁcant if
P<. 05. All analyses were performed with SPSS(version 11.5
for Windows).
3.Results
The HIV-IR group had signiﬁcantly lower skeletal muscle
insulin sensitivity (4.4 ± 0.9mg glucose per kg lean body
mass per min, P<. 001), assessed by the hyperinsulinemic-
euglycemic clamp, than either the control group (10.6mg ±
0.7) or the HIV-IS group (9.7 ± 0.6) (Table 1).
Expression of the PPARγ gene in muscle tissue was
l o w e ri nH I V - i n f e c t e ds u b j e c t sw i t hi n s u l i nr e s i s t a n c e
(HIV-IR group) compared to uninfected subjects (control,
Figure 1(a))b ys i m p l et-test (P = .03). If the three groups,
control, HIV-infected insulin sensitive (HIV-IS) and HIV-
IR are compared with a correction for multiple testing,
the diﬀerences among the groups are not signiﬁcant. The
expressionofthreePPAR-responsivegenes,lipoproteinlipase
(LPL),steroylCoA-desaturase(SCD)andmuscle-typecarni-
tine palmitoyl transferase-1 (CPT-1) [32, 33], are also shown
in Figure 1. The expression of lipoprotein lipase (LPL) was
signiﬁcantly reduced in both groups of HIV-infected sub-
jects, relative to uninfected controls (P<. 01, Figure 1(b)).
Theexpressionofmuscle-typecarnitinepalmitoyltransferase
1 (CPT-1) was not signiﬁcantly diﬀerent among control,
HIV-IS or HIV-IR groups (Figure 1(c)), and the expression
of steroyl CoA-desaturase (SCD) was not diﬀerent across
groups (Figure 1(d)).
Rosiglitazone administration to HIV-infected subjects
with insulin resistance signiﬁcantly improved skeletal muscle
insulin sensitivity, as previously reported for a subgroup of
these subjects [12]. Treatment with rosiglitazone resulted
in a small, but not signiﬁcant (P = .08), increase in the
expression of LPL (Table 2) and a signiﬁcant increase (P =
.03) in SCD expression (Table 2). There was a small (∼20%)
but signiﬁcant (P = .018) decrease in CPT-1 expression
(Table 2). Although the overall expression of PPARγ was
not signiﬁcantly diﬀerent before and after treatment with
rosiglitazone (Table 2), this was mainly due to the variable
responseamongindividualsubjectswitharangeofresponses


















































































Figure 1: Gene expression for the gamma isoform of peroxisome proliferator-activated receptor (PPARγ) (a), lipoprotein lipase (LPL) (b),
carnitine palmitoyl transferase-1 (CPT-1) (c), and steroyl CoA-desaturase (SCD) (d) normalized to the expression of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) in subjects without HIV disease (control) and subjects with HIV disease who were either sensitive to
insulin (HIV-IS) or resistant to insulin (HIV-IR). Insulin sensitivity was determined with the hyperinsulinemic euglycemic clamp. Gene
expression is expressed as mean with SEM and has been multiplied by 100. #The expression of PPARγ was signiﬁcantly lower in the HIV-IP
group than in the control group by simple t-test (P = .03), in (a). ∗The expression of LPL in both the HIV-IS and HIV-IR groups were
signiﬁcantlylower than controls (P<. 01), in (b).
change in insulin sensitivity in response to rosiglitazone,
1.56 ± 1.05, included a range of response from 0.88–2.59
fold.
T h ec h a n g ei ne x p r e s s i o no ft h eP P A R γ gene following
rosiglitazone treatment was signiﬁcantly correlated with the
improvement in insulin sensitivity (Figure 2, r = 0.87,
P<. 002). The improvement in PPARγ expression was also
signiﬁcantly associated with changes in expression of CPT-1
(r = 0.75, P<. 009), but not LPL (r = 0.37, P = .30) or SCD
(r = 0.11, P = .77).
In addition, the low level of expression of PPARγ in
human vastus lateralis musclecompared to otherisoforms of
PPAR, that is, PPARα and PPARδ, was also conﬁrmed. The
level of the expression of PPARγ was approximately 5% that
of PPARδ and 10% that of PPARα (Figure 3).
To rule out the possibility of contamination of mus-
cle biopsy specimens with adipose tissue, the expression
of the adipose-speciﬁc gene, adiponectin, was assessed.
Adiponectin expression in muscle tissue was 1000-fold lower
than observed in adipose tissue in preliminary studies (data
not shown). In addition, there was no change in adiponectin
expression inthemusclespecimensfollowing treatment with
rosiglitazone, as would be expected if there was signiﬁcant
contamination of the muscle specimens with adipose tissue.
4.Discussion
Treatment ofHIV-associated insulinresistance with aPPARγ
agonist (rosiglitazone) signiﬁcantly improved insulin sensi-
tivity assessed with the hyperinsulinemic euglycemic clamp.
Hepatic gluconeogenesis is suppressed during the clamp by
the infused insulin. The plasma glucose concentration is
maintained at 90mg/dl (5mM) by infusion, functionally
eliminating the hepatic GLUT2 transporters (Km 17mM)
from signiﬁcantly contributing to glucose disposal. Thus,
this procedure measures insulin sensitivity of peripheral
tissue, primarily muscle [34]. The strong association of
the improvement in insulin sensitivity with an increase inPathology Research International 5
Table 2: Gene expression in muscle tissue of insulin-resistant HIV
infected subjects before and after treatment with rosiglitazone.




LPL 24.7 ±2.83 0 .2 ±4.81 .27 ±0.16 NS
CPT-1 57.6 ±5.34 4 .7 ±4.30 .81 ±0.08 .018
PPARγ 0.954 ± 0.177 0.942 ±0.185 1.12 ±0.21 NS
ACPR30 4.14 ±2.15 .13 ±2.61 .76 ±0.58 NS
SCD 16.3 ±7.22 5 .3 ±9.61 .67 ±0.27 .03
PPARα 34.5 ±6.23 5 .2 ±5.01 .17 ±0.14 NS
All gene expression data before and after treatment with rosiglitazone
(8mg/d for 12 weeks) are expressed as means ± SEM and nor-
malized to the expression of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH).LPL:lipoproteinlipase;CPT-1:carnitinepalmitoyltransferase-1;
PPARγ :peroxisome proliferator-activated receptor γ; ACPR30: Adiponect-
i n ;S C D :s t e r o y lC o A - d e s a t u r a s e ;a n dP P A R α :peroxisome proliferator-
activated receptor α. Statistical signiﬁcance was determined with a paired
t-test (SPSS).
PPARγ expression in muscle tissue following treatment with
aP P A R γ agonist, rosiglitazone [23, 24], (Figure 2, r = 0.87,
P = .001) suggests that a direct eﬀect of rosiglitazone on
muscle tissue may be important in mediating the improve-
ment in insulin sensitivity. However, care must be taken
to rule out an indirect eﬀect on muscle biopsy material
mediated by a direct eﬀect on contaminating adipose tissue.
Of the multiple isoforms of the PPARs, the expression of
PPARγ is much lower in muscle than either that of PPARα or
PPARδ (Figure 3)a n d[ 35, 36]. In the present study, PPARγ
expression was approximately 10% that of PPARα and only
5% of PPARδ (Figure 3). The primary tissue expressing the
PPARγ isoform is adipose tissue with little expression in
liver and muscle [37], suggesting that adipose tissue may
be the primary site of action for the PPARγ agonists like
rosiglitazone. Of particular relevance to the present study is
theabilityofadiposetissuetosecreteadiponectininresponse
to treatment with PPARγ agonists such as rosiglitazone [38,
39] particularly a high-molecular-weight isoform [40, 41]
associated with improved insulin sensitivity.
However, the improvement in insulin sensitivity asso-
ciated with increased adiponectin was associated with
improvementsinliverphysiology,notmuscle[40–43].Inthe
current study, insulin sensitivity was assessed with the clamp
procedure, which reﬂects sensitivity in muscle tissue and not
in the liver.
The changes in the circulating concentrations of adi-
ponectin including the concentration of the high-molecular
weight isoform were not associated with the improvement in
insulin sensitivity, as measured by the clamp. Therefore, it
seems unlikely that the improvement in insulin sensitivity in
the current study was mediated by an eﬀect of rosiglitazone
on adipose tissue resulting in the release of adiponectin with
as u b s e q u e n te ﬀect on muscle tissue.
An error in interpretation might also arise if there was
signiﬁcant contamination of the muscle biopsy with adipose
tissue. To test for this possibility, the muscle samples were
analyzed for the expression of the adiponectin gene, which
is exclusively expressed in adipose tissue [44]. The level
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Figure 2: Relationship of changes in PPARγ expression with
changes in insulin sensitivity after rosiglitazone treatment. Cor-
relation of the changes in the expression of the peroxisome
proliferator-activated receptor-gamma (PPARγ)g e n en o r m a l i z e d
to the expression of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and the changes in insulin sensitivity in HIV infected
subjects with insulin resistance before and after treatment with
the PPARγ agonist, rosiglitazone. The data are expressed as the
























Figure 3: PPAR isoforms in skeletal muscle. Peroxisome
proliferator-activated receptor PPAR isoforms (PPARδ,P P A R α,
PPARγ)levels normalized to the expression of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) in skeletal muscle in subjects
without HIV infection (control) and subjects with HIV disease
who were either sensitivity to insulin (HIV-IS) or resistant to
insulin (HIV-IR). Insulin sensitivity was determined with the
hyperinsulinemic euglycemic clamp. The data are expressed as
mean and SEM multiplied by 100.
of expression of adiponectin in these muscle samples is
approximately 1000-fold lower than in adipose tissue and
completely unresponsive to the treatment with rosiglitazone
(Table 2)makingitmostunlikelythattheobservedresponses
in PPARγ gene expression were due to adipose tissue
contamination of the muscle biopsies.6 Pathology Research International
It seems likely, therefore, that the improvement in
peripheral insulin sensitivity was related to a direct action of
rosiglitazone on muscle tissue PPAR-regulated gene expres-
sionratherthananindirecteﬀectmediatedbyadiposetissue.
This conclusion is consistent with animal experiments indi-
catingthattreatmentwithPPARγ agonistscanactdirectlyon
muscletissue [45].The study of Kimet al. demonstrated that
adipose tissue was not necessary for rosiglitazone-mediated
improvement in insulin sensitivity. Glucose uptake into
muscle was normalized following rosiglitazone treatment
of the insulin-resistant A-ZIP/F-1 fatless mouse, although
hepatic insulin resistance was not corrected, suggesting that
a normalization of hepatic insulin resistance did require
an adipose tissue-derived factor [45]. Development of a
mouse model with a speciﬁc deletion for muscle PPARγ also
suggested that improvement in insulin sensitivity by PPARγ
agonists (both troglitazone and rosiglitazone) required the
presence of muscle PPARγ [46]. Other studies in humans
have also conﬁrmed the presence of PPARγ in muscle tissue
both with immumohistochemistry [47]a n dw i t hR T - P C R
[48, 49] adding additional support for the hypothesis of a
direct eﬀect on PPARγ in muscle tissue.
The present study also assessed the expression of genes
known to be regulated by PPARγ in muscle tissue, includ-
ing muscle-type carnitine palmitoyl transferase-1 (CPT-1),
lipoprotein lipase (LPL), and steroyl CoA-desaturase (SCD)
[18, 50] in response to treatment with a PPARγ agonist,
rosiglitazone. Treatment with rosiglitazone resulted in a
signiﬁcant stimulation of SCD expression (Table 2)w h i c h
is consistent with an increase in SCD expression in muscle
samples reported by Tonelli et al. forpioglitazone (adiﬀerent
PPARγ agonist) treatment of subjects with type 2 diabetes
[40]. In the present study there was also a small, but
signiﬁcant, decrease in CPT-1 and no signiﬁcant change
in the expression of LPL. The change in CPT-1 expression
correlated with the change in PPARγ expression (r = 0.95,
P<. 001), but the changes in expression of SCD (r =
0.11, P = .8) and LPL (r = 0.37, P = .3) were not
signiﬁcantlycorrelatedwithchangesinPPARγ.Thus,ther eis
not an apparent generalized increased expression in PPARγ-
regulated genes in muscle tissue in response to treatment
with a PPARγ agonist, but rather selective regulation of
PPARγ-regulated genes.
Although the relationship of changes in PPARγ expres-
sion with changes in expression of CPT-1 following treat-
ment were highly signiﬁcant (r = 0.95, P<. 001), overall the
expression of CPT-1 was lower after treatment than before.
This somewhat paradoxical result has also been reported in
a study in diabetic Zucker rats treated with a PPARγ agonist
(GW1929). In that study a number ofdiﬀerencesin response
between adipose tissue and muscle tissue in response to
treatment with a PPARγ agonist were noted with the
expression of multiple genes involved in fatty acid transport
and oxidation increased in adipose tissue but decreased in
muscle tissue [33]. A somewhat diﬀerent conclusion was
reported by Wilmsen et al. in human muscle cells from
diabetic subjects in culture exposed to rosiglitazone [51]
where treatment of the cultures with a series of PPARγ
agonists resulted in increased uptake and oxidation of fatty
acids. This in vitro result was not seen in an in vivo study of
rats treated with a PPARγ agonist [52].
The present study also suggests that there is defective
gene expression associated with HIV-infection whether or
not insulin resistance is present. The expression of lipopro-
tein lipase (LPL, Table 2) was signiﬁcantly reduced in those
individuals infected with HIV regardless of their insulin
sensitivity. Although a correlation of human skeletal muscle
LPL expression with PPARα expression has been reported
[53], it is unlikely that the reduced expression of LPL in
subjects infected with HIV was due to lower levels of PPARα
levels. PPARα expression was not reduced in HIV-insulin
sensitive individuals comparedtocontrolsubjects (Figure 3).
It seems more likely that the reduction in LPL expression
with HIV disease was due to factors other than PPAR-
regulation of the LPL promoter region.
In conclusion, this study suggests that human muscle
tissue may be responsive to the eﬀects of the PPARγ agonist,
rosiglitazone, and that the changes in expression of the
PPARγ gene in muscle tissue may be a contributing factor
to the improvement in insulin sensitivity observed following
rosiglitazone administration (Figure 2).
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